Home drug plans Page 18

Keyword: drug plans

391 results found
Specialty drug prior authorization a useful tool for plan sponsors

Analysis by Telus Health found specialty drugs have grown from 11 per cent of total private drug plan claims costs in 2008 to 30 per cent in 2019 and require effective management to ensure sustainability of health benefits plans, said Suzanne Lepage, private health plan strategist, during a session at Benefits Canada’s Face to Face […]

Health Canada delaying drug pricing reforms until July

Health Canada says it’s delaying the implementation of long-awaited changes to Canada’s drug-pricing regime by another six months. A spokesman for the department, says the amendments to patented medicine regulations, which were set to take effect Jan. 1, will now come into force on July 1. Geoffroy Legault-Thivierge says the postponement is intended to give pharmaceutical manufacturers […]

How plan sponsors can contain rising drug costs in 2021

With drug costs for plan sponsors steadily rising in recent years, keeping budgets down is top of mind as they plan for 2021. “The biggest concern for plan sponsors is sustainability,” said Shawn O’Brien, principal of data enablement and drug, health, dental product roadmap for Telus Health, in a press release. “They have to find a […]

  • By: Staff
  • December 18, 2020 April 23, 2021
  • 09:03
A legislative update on provincial biosimilar policies

When the City of Toronto switched benefits plan insurers in 2017, it changed its coverage for biologics and biosimilars. Under its previous plan, the City reimbursed employees for the drugs their doctors recommended and prescribed; now, it follows its new insurer’s mandatory biosimilars policy, while grandfathering any plan member who was already taking a biologic […]

Plan members using EAP, virtual care to support mental health during pandemic

The coronavirus pandemic has significantly increased plan members’ willingness to seek help for their mental-health concerns and to access video or telephone counselling, said Julie Gaudry, senior director of group insurance for RBC Insurance, during Benefits Canada’s 2020 Mental Health Summit on Nov. 12. An RBC Insurance survey of plan members found two-thirds (67 per cent) […]

Understanding the journey of a patient with depression

Defining depression may seem simple, but it’s actually a complex mental-health disorder that can look different for every person it affects. That’s why a personalized treatment plan is crucial to alleviate symptoms and promote recovery, said Dr. Diane McIntosh, psychiatrist and chief neuroscience officer at Telus Health, during a session at Benefit Canada’s 2020 Mental Health […]

  • By: Sonya Felix
  • November 27, 2020 November 27, 2020
  • 07:56
Telus Health, Canada Life, Innomar taking drug prior authorization online

Telus Health is partnering with Canada Life Assurance Co. and Innomar Strategies Inc. to launch Canada’s an electronic drug prior authorization solution. The pilot program will test the digitized process to fulfill prior authorization submissions for real prescription cases and evaluate its impact on process efficiency, consistency of adjudication results and the overall plan sponsor and member […]

  • By: Staff
  • November 11, 2020 November 11, 2020
  • 15:00
Group health plan costs expected to rise in 2021: report

The costs of employer-provided health plans in Canada are expected to rise seven per cent next year, outpacing general inflation by more than five per cent, according to a new report by Aon Canada. Contributing factors include higher drug prices, the impact of non-communicable health risks and the continued introduction of new and expensive therapies. Indeed, […]

  • By: Staff
  • October 29, 2020 October 29, 2020
  • 15:15
CLHIA’s Ontario budget submission highlights drug access, inflexible pension plans

In its 2020 budget submission to the Ontario government, the Canadian Life and Health Insurance Association is highlighting a lack of access to affordable prescription drugs and inflexible pension plans. With respect to prescription drugs, the CLHIA noted it supports the federal Patented Medicine Prices Review Board reforms, which were introduced on Friday. “It is crucial that the […]

  • By: Staff
  • October 26, 2020 October 26, 2020
  • 15:15
PMPRB publishes new guidelines on drug pricing in Canada

The Patented Medicine Prices Review Board published its new guidelines on Friday. The guidelines, which will take effect on Jan. 1, 2021, aim to modernize Canada’s pricing framework for patented medicines. They explain the steps that will typically be taken by the PMPRB’s staff in assessing whether a patented medicine appears to be priced excessively in Canada. The […]

  • By: Staff
  • October 23, 2020 October 23, 2020
  • 15:15